Search results
What You Need to Know About Humira's Low-Cost Competitors
Verywell Health via Yahoo News· 10 months agoAt least nine Humira biosimilars are coming to market, along with promises of lower costs for...
AbbVie's Humira gets a U.S. rival, but costs could stay high
Reuters via Yahoo Finance· 1 year agoU.S. patients will finally get access to cheaper versions of AbbVie Inc’s blockbuster arthritis drug...
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
Investor's Business Daily· 1 year agoAbbVie's two-decade Humira monopoly came to an end Tuesday after Amgen launched its biosimilar...
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View
Zacks via Yahoo Finance· 11 months agoAbbVie Inc. ABBV reported adjusted earnings of $2.91 per share for second-quarter 2023, beating the...
CVS will remove AbbVie's Humira from some drug reimbursement lists in April
Reuters via Yahoo News· 6 months agoCVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira...
Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised
Zacks via Yahoo Finance· 1 year agoAmgen AMGN reported first-quarter 2023 earnings of $3.98 per share, which beat the Zacks Consensus...
Boehringer launches 81% discounted biosimilar of AbbVie's Humira
Reuters via Yahoo News· 9 months ago(Reuters) -Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar...
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Reuters via Yahoo Finance· 2 months agoCigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no...
3 Stocks That Recently Raised Their Guidance for the Year
Motley Fool· 10 months agoGDP grew at a rate of 2.4% in the second quarter as the economy did better than expected. And many...
Mark Cuban's online pharmacy set to launch Humira biosimilar
Reuters via AOL· 12 months agoMark Cuban Cost Plus Drugs, an online pharmacy launched by the billionaire to sell drugs directly to customers at low prices, should soon begin selling Coherus BioSciences's biosimilar version ...